ClinicalTrials.gg
Not yet recruitingNCT06628245Updated Oct 4, 2024

The Dubousset Functional Test in Lumbar Spinal Stenosis

An observational study in Lumbar Spinal Stenosis, sponsored by Alanya Alaaddin Keykubat University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Alanya Alaaddin Keykubat University · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to investigate the validity and reliability of Dubousset Functional Test in the patients with lumbar spinal stenosis.

02

Conditions studied

  • Lumbar Spinal Stenosis

Browse trials for

Keywords

  • Lumbar Spinal Stenosis
  • Functional Status
  • Dubousset Functional Test
  • Reliability
  • Validity
03

In context

Spinal Stenosis

469 studies on the registry are indexed under Spinal Stenosis; 106 are open to participants now.

This study's planned enrollment of 60 is below the median of 118 across 156 observational studies indexed under Spinal Stenosis.

Browse Spinal Stenosis studies →

Lead sponsor

Alanya Alaaddin Keykubat University is the lead sponsor of 49 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Sixty patients with lumbar spinal stenosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-65 years, diagnosed with chronic pain (more than three months) due to lumbar spinal stenosis.

Exclusion criteria

Exclusion Criteria:

  • Those with fractures, pregnancy, a disease that would prevent physical exertion, those with a body mass index (BMI) of 40 kg/m2 and above, and those with major musculoskeletal or neurological disorders that cause gait disturbance will be excluded from the study.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Dubousset Functional Test

    The four test components included the Up and Walking Test (unassisted sit-to-stand from a chair, walk forward/backward 5 meters \[no turn\], then unassisted stand-to-sit), Steps Test (ascend three steps, turn, descend three steps), Down and Sitting Test (stand-to-ground, followed by ground-to-stand, with assistance as needed), and Dual-Tasking Test (walk 5 meters forwards and back while counting down from 50 by 2).

    Time frame: 10 minutes

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06628245
Lead sponsor
Alanya Alaaddin Keykubat University
Responsible party
Ayse Unal (Associate Professor, Alanya Alaaddin Keykubat University) — Principal investigator
First posted
Oct 4, 2024
Start date
Dec 2024 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Oct 4, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion